Novartis announces Mr Bruno Stringini as the new president for its oncology division
Singapore: Swiss drug giant Novartis, announced on June 1, that it had appointed Mr Bruno Strigini as the president of its oncology division. Mr Stringini had earlier served Merck & Co. as the president for Europe/Canada region, comprising 37 countries with over 10,000 associates.
Novartis had declared Alessandro Riva as the interim president, following resignation of Mr Herve Hoppenot in mid-January 2014. With 25 years of experience in the global healthcare industry, pharmaceuticals, animal health as well as vaccines, Mr Strigini's association with Novartis is believed to add a lot of expertise knowledge to the company's innovation and business.
Through his career, Mr Stringini has held various senior executive positions with eminent organizations like, Schering-Plough, UCB-Celltech and SmithKline Beecham. Mr Stringini has a doctorate in pharmacy from the University of Montpellier, France, and an MBA degree from Lausanne, Switzerland.
Previous organizational experience of Mr Bruno include chief roles like president of international operations, president of Japan and Asia-Pacific, and senior vice-president and head of global marketing and business development, as well as managing director positions in New Zealand, the UK and Spain.
Mr Bruno is also currently the member of Executive Committee for the European Federation of Pharmaceutical Industries and Associations (EFPIA)and member of the Academie Nationale de Pharmacie in France.
